Evidence map›Paper›PMID 28061828›Full record

ArticleBMC nephrology2017

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.

Danhua Shu, Feifei Xu, Zhen Su, Ji Zhang, Chaosheng Chen, Jianna Zhang, Xiaokai Ding, Yinqiu Lv, Haixia Lin, Peipei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Hyperuricemia aggravates the progression of IgA nephropathy.International urology and nephrology · 2022
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Danhua ShuDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Feifei XuDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhen SuDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. cnsuzhen@hotmail.com.
Ji ZhangDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chaosheng ChenDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jianna ZhangDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiaokai DingDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yinqiu LvDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Haixia LinDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Peipei HuangDepartment of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere were few related studies aiming to severe IgA nephropathy (IgAN) which could progress rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and promising precautions is essential.

methodsA single center case-control study was performed. Fifty ESRD patients with the primary cause of IgAN and a short renal survival time of less than ten years after diagnose were enrolled in the case group. One hundred IgAN patients with a renal survival time of more than ten years were enrolled in the control group. IgA Oxford classification scores, clinical data at baseline and during the follow-up were collected. Multivariate logistic regression was used to investigate factors associated with the development of ESRD.

resultsThere were significant differences in baseline clinical data between these two groups, as well as the constituent ratio of Oxford MEST-score. Distinct differences were observed in time-average uric acid(TA-UA), time-average hemoglobin(TA-Hb), time-average albumin(TA-Alb), time-average total cholesterol(TA-TC) and time-average urinary protein(TA-P) during the follow-up. In multivariate logistic models, IgA Oxford score M1(OR = 5.10, P = 0.018) and eGFR(OR = 0.97, P = 0.039) at biopsy, TA-UA (OR = 2.06, P = 0.026) and TA-Hb (OR = 0.53, P = 0.022) during the follow-up were identified independent factors for developing ESRD.

conclusionIgAN patients with pathological assessment of M1, low baseline eGFR, TA-Hb and high TA-UA were more likely to progress to ESRD, and should be paid more attention. Appropriate regulations of UA, Hb and urine protein after diagnose may be a promising treatment.

Indexed as

AdultCase-Control StudiesCholesterolDisease ProgressionFemaleGlomerular Filtration RateGlomerulonephritis, IGAHemoglobinsHumansKidneyKidney Failure, ChronicLogistic ModelsMaleMiddle AgedMultivariate AnalysisProteinuriaCholesterolHemoglobinsSerum AlbuminUric AcidEnd stage renal diseaseFollow-up clinical dataIgA nephropathyOxford classification

Identifiers

PMID28061828
PMCPMC5219698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.